Drugs and Devices

FDA approves Ibrance for postmenopausal women with metastatic breast cancer

On February 3, the U.S. Food and Drug Administration (FDA) approved Ibrance (palbociclib) to treat advanced metastatic breast cancer. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares